NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

DMAC

DiaMedica Therapeutics Inc

Jun 30 • 04:00PM ET

3.90

Dollar change +0.06
Percentage change 1.56	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RNA EBS ARWR AKBA ALKS RIGL LGND AKRO ANVS

| Held by: VTI VXF IWM IWO IWC RSSL AVSC UWM URTY ITWO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	43.69%	Shs Outstand	42.86M	Perf Week	6.85%
Market Cap	167.24M	Forward P/E	-	EPS next Y	-0.80	Insider Trans	0.00%	Shs Float	24.15M	Perf Month	-6.92%
Enterprise Value	131.24M	PEG	-	EPS next Q	-0.19	Inst Own	17.80%	Short Float	5.11%	Perf Quarter	2.09%
Income	-27.00M	P/S	-	EPS this Y	-29.44%	Inst Trans	11.05%	Short Ratio	7.79	Perf Half Y	-25.86%
Sales	0.00M	P/B	4.92	EPS next Y	-2.58%	ROA	-61.30%	Short Interest	1.23M	Perf YTD	-28.18%
Book/sh	0.79	P/C	4.60	EPS next 5Y	-14.05%	ROE	-67.25%	52W High	6.82 -42.80%	Perf Year	31.76%
Cash/sh	0.85	P/FCF	-	EPS past 3/5Y	2.58% 7.39%	ROIC	-79.03%	52W Low	2.65 47.17%	Perf 3Y	71.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.49% 7.25%	Perf 5Y	-43.88%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-16.66%	Oper. Margin	-	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.96	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.02	EPS Q/Q	-32.57%	SMA20	0.14%	Beta	1.17	Target Price	9.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-1.92%	Rel Volume	1.10	Prev Close	3.84
Employees	28	LT Debt/Eq	0.01	Earnings	May 13 AMC	SMA200	-17.53%	Avg Volume	158.36K	Price	3.90
IPO	Jan 04, 2008	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	174,441	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Initiated	H.C. Wainwright	Buy	$7
Apr-24-24	Resumed	Craig Hallum	Buy	$8
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform	$7
Apr-09-21	Initiated	Oppenheimer	Outperform	$27
Feb-17-21	Initiated	ROTH Capital	Buy	$38
Oct-30-20	Initiated	Guggenheim	Buy	$16
Jul-08-20	Initiated	Maxim Group	Buy	$14
Apr-30-19	Initiated	Dougherty & Company	Buy	$8
Mar-05-19	Initiated	Lake Street	Buy	$9

Jun-24-25 08:30AM	DiaMedica Therapeutics Announces Inclusion in the Russell 2000 and Russell 3000 Indexes (Business Wire)
May-22-25 08:30AM	DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 (Business Wire)
May-19-25 09:00AM	DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia (Business Wire)
May-15-25 03:09AM	DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
May-14-25 11:14PM	Q1 2025 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
04:30PM	Loading…
04:30PM	DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference ESOC 2025 (Business Wire)
May-13-25 04:30PM	DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights (Business Wire)
May-08-25 04:00PM	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May (Business Wire)
May-07-25 08:30AM	DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025 (Business Wire)
Apr-15-25 08:54PM	DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve (Seeking Alpha)
Mar-19-25 03:00AM	DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Mar-18-25 10:22PM	Q4 2024 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.02%
Mar-17-25 04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results (Business Wire)
Mar-11-25 08:23AM	DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 (Business Wire)
Feb-24-25 08:30AM	DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors (Business Wire)
08:15AM	Loading…
Feb-20-25 08:15AM	DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke (Business Wire)
Feb-10-25 04:15PM	DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-03-24 08:25AM	DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia (Business Wire)
Nov-15-24 02:06AM	Q3 2024 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-24 04:20PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results (Business Wire)
04:05PM	DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia (Business Wire)
Nov-12-24 08:23AM	DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference (Business Wire)
Nov-06-24 08:32AM	DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 (Business Wire)
Oct-10-24 05:28AM	DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial (Clinical Trials Arena)
Oct-09-24 08:27AM	DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia (Business Wire)
Sep-04-24 04:15PM	DiaMedica Therapeutics Upcoming Conference Participation (Business Wire)
Aug-07-24 04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 09:40AM	Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? (Zacks) +5.18%
08:20AM	DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 (Business Wire)
Jul-11-24 08:00AM	DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia (Business Wire) +6.67%
08:00AM	Loading…
Jul-01-24 08:00AM	DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement (Business Wire)
Jun-26-24 08:15AM	DiaMedica Therapeutics Announces $11.8 Million Private Placement (Business Wire) +30.97%
08:00AM	DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia (Business Wire)
May-13-24 12:08PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 10:54PM	DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19% -6.34%
04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results (Business Wire)
May-02-24 08:55AM	DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 (Business Wire)
Apr-18-24 10:06AM	DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch (Zacks)
Apr-17-24 04:08PM	DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke (Business Wire) +9.70%
Apr-15-24 09:35AM	DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-19-24 09:53PM	DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 (InvestorPlace)
04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results (Business Wire)
Jan-29-24 04:13PM	DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference (Business Wire)
Jan-22-24 08:23AM	DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer (Business Wire)
Dec-04-23 02:56PM	Billionaire Lee Coopermans 10 Stock Picks with Huge Upside Potential (Insider Monkey)
Nov-15-23 12:15PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 10:54PM	Q3 2023 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
02:53PM	DiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
Nov-13-23 04:28PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results (Business Wire)
Nov-09-23 08:25AM	DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023 (Business Wire)
Nov-06-23 08:23AM	DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 (Business Wire)
Sep-12-23 08:13AM	DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer (Business Wire)
Sep-06-23 08:35AM	DiaMedica Therapeutics to Participate at Lake Streets 7th Annual Best Ideas Growth Conference (Business Wire)
Aug-31-23 09:40AM	Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-15-23 09:19PM	Q2 2023 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:13PM	DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-08-23 08:32AM	DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023 (Business Wire)
Jul-18-23 08:30AM	DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference (Business Wire)
Jun-26-23 08:30AM	DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement (Business Wire)
Jun-21-23 08:39AM	DiaMedica Therapeutics Announces $37.5 Million Private Placement (Business Wire) -6.91%
08:15AM	DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke (Business Wire)
May-30-23 08:29AM	DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors (Business Wire)
May-17-23 01:50PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-16-23 09:38PM	Q1 2023 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -10.77%
May-15-23 04:28PM	DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results (Business Wire) +22.72%
May-13-23 09:23AM	Bullish DiaMedica Therapeutics Insiders Loaded Up On US$5.2m Of Stock \ (Simply Wall St.)
May-08-23 08:50AM	DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023 (Business Wire)
Apr-11-23 08:41AM	DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer (Business Wire)
Mar-31-23 04:29AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-28-23 04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results (Business Wire)
Mar-20-23 04:17PM	DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023 (Business Wire)
Mar-13-23 08:00AM	DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
Mar-06-23 08:30AM	DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors (Business Wire)
Dec-31-22 08:02AM	We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth (Simply Wall St.)
Dec-04-22 07:04AM	Insider Buying: The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director Just Bought 38% More Shares (Simply Wall St.)
Nov-09-22 04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results (Business Wire)
Nov-07-22 08:32AM	DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022 (Business Wire)
Nov-02-22 12:00PM	What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock (Zacks)
Oct-31-22 08:32AM	DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference (Business Wire)
Oct-26-22 04:30PM	DiaMedica Therapeutics Provides Update on ReMEDy2 Trial (Business Wire) -15.49%
Oct-14-22 09:49AM	Insiders rewarded with a US$114k addition on top of their US$676k purchase as DiaMedica Therapeutics Inc. (NASDAQ:DMAC) hits US$41m (Simply Wall St.)
Sep-14-22 08:30AM	DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations (Business Wire) +8.16%
Sep-06-22 04:10PM	DiaMedica Therapeutics to Present at Lake Streets 6th Annual Best Ideas Growth Conference (Business Wire) -21.02%
Aug-10-22 05:20PM	DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results (Business Wire) +9.83%
Aug-04-22 08:12AM	DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022 (Business Wire) +5.59%
Aug-01-22 04:32PM	DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022 (Business Wire) -6.06%
Jul-21-22 04:31PM	CORRECTION: Thomas Von Koch Acquires Common Shares of DiaMedica Therapeutics Inc. (Newsfile) +5.79% +11.68%
03:50PM	Thomas Von Koch Acquires Common Shares of DiaMedica Therapeutics Inc. (Newsfile)
Jul-14-22 07:05AM	We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate (Simply Wall St.) -5.22%
Jul-07-22 07:37AM	FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why (Benzinga) -37.62%
Jul-06-22 04:41PM	DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199 (Business Wire)
May-25-22 04:15PM	DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022 (Business Wire)
May-07-22 09:05AM	Recent gains in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) help add back some value on insider purchases worth US$630k, still down US$149k (Simply Wall St.)
May-04-22 04:32PM	DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results (Business Wire) -5.34%
Apr-28-22 08:15AM	DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022 (Business Wire)
Mar-14-22 04:45PM	DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results (Business Wire) -9.06%
Mar-08-22 08:13AM	DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022 (Business Wire)
Feb-04-22 05:52AM	DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pilnik Richard D.	Director	Apr 07 '25	Option Exercise	2.11	24,000	50,640	312,995	Apr 08 04:41 PM
Giuffre Randall Michael	Director	Feb 13 '25	Option Exercise	2.56	17,000	43,570	392,412	Feb 18 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DMAC

DiaMedica Therapeutics Inc

Upgrade your FINVIZ experience